Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial

R B M Landewe,D M F M Van Der Heijde,B A Masek,L B A Van De Putte,J M G W Wouters,J G A Houbiers,J M Van Laar,G A W Bruyn,P C P M Verschueren,A M M Miltenburg,A E Voskuyl,F Van Den Bosch,J In'T Hout,J J W Bijlsma,F C Breedveld,F H J Van Den Hoogen,J H Meijerink,F De Keyser

doi:10.1136/ard.2009.117234

Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial

R B M Landewe, D M F M Van Der Heijde + Show 16 more

https://doi.org/10.1136/ard.2009.117234

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Sep 23, 2009
Citations: 21

#HC Gp-39 #Intranasal Treatment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundAutoantigen-specific immunotherapy by mucosal tolerance induction via the intranasal route is an attractive therapeutic option for the treatment of autoimmune diseases, including rheumatoid arthritis (RA). Human cartilage glycoprotein-39 (HC gp-39)...

Full Text